The EPS miss is minor and offset by improved cash position and regulatory progress. The key catalyst is initial clinical data expected in 2026 — monitor for presentation date. No immediate trading trigger; stock likely range-bound until data readout.
Price Chart
Executive Summary
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FDA agreement for outpatient dosing and expansion into rheumatoid arthritis, with initial clinical data expected in 2026. Cash runway into 2029 provides stability, but the EPS miss and lack of near-term catalysts keep sentiment neutral.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.37 vs consensus -$0.36 (miss of 2.8%)
- No revenue reported (pre-revenue biotech)
- Cash balance: $266.7M as of March 31, 2026, expected to fund operations into 2029
- Net loss: $27.8M for Q1 2026, improved from $32.0M in Q1 2025
- FDA agreement to allow outpatient dosing, re-dosing, and expansion into rheumatoid arthritis
- Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026
Financial Impact
EPS miss of $0.01 vs consensus; net loss improved by $4.2M YoY; cash burn of ~$28.4M in Q1
Risk Factors
- Clinical trial failure or disappointing data
- Dilution risk if cash runway shortens
- Regulatory setbacks despite recent FDA agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.33 $2.91 | ▼ −24.89% | ▼ −25.95% | $2.56 (−9.66%) |
May 12, 2026 20w ago | Press Release | $3.06 $2.76 | ▼ −9.80% | ▼ −9.19% | $2.56 (−16.50%) |
Apr 15, 2026 24w ago | Press Release | $2.80 $3.06 | ▲ +9.29% | ▲ +3.47% | $2.56 (−8.75%) |
Apr 6, 2026 25w ago | EFFECT | $2.36 $3.02 | ▼ −27.97% | ▼ −18.98% | $2.56 (−8.26%) |
Mar 26, 2026 27w ago | 8-K | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.56 (−19.39%) |
Mar 25, 2026 27w ago | S-3 | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.56 (−19.39%) |
Mar 25, 2026 27w ago | Press Release | $2.14 $2.92 | ▲ +36.45% | ▲ +25.78% | $2.56 (+19.39%) |
Feb 28, 2026 30w ago | Institutional Cluster | $2.70 $2.00 | ▼ −25.93% | ▼ −17.99% | $2.56 (−5.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access